(3-iodobenzyl)trozamicol profile

(3-iodobenzyl)trozamicol is a **radiolabeled derivative of trozamicol**, a drug used to treat **peripheral vascular disease** by improving blood flow. It's important for research because it allows scientists to **study the distribution, metabolism, and pharmacokinetics of trozamicol** in living organisms using **positron emission tomography (PET)**.

Here's a breakdown:

* **Trozamicol:** A drug used to improve blood flow in the legs and feet.
* **(3-iodobenzyl)trozamicol:** A modified version of trozamicol where an iodine-123 atom has been added to a specific position in the molecule.
* **Iodine-123:** A radioactive isotope that emits positrons, making it suitable for use in PET imaging.
* **PET imaging:** A technique that uses radioactive tracers to visualize the distribution and activity of certain molecules in the body.

**Why is this important for research?**

* **Understanding drug distribution:** By using (3-iodobenzyl)trozamicol in PET imaging, researchers can track the movement of the drug throughout the body. This can provide valuable insights into how the drug reaches its target tissues and how it is eliminated.
* **Investigating drug metabolism:** PET imaging with this tracer can reveal how the body processes the drug and how it is broken down. This information is crucial for optimizing drug dosage and minimizing side effects.
* **Assessing drug efficacy:** By visualizing the drug's action in the body, researchers can assess the effectiveness of trozamicol in treating peripheral vascular disease and potentially identify new applications for the drug.

In short, (3-iodobenzyl)trozamicol is a valuable tool for research because it provides a non-invasive way to study the distribution, metabolism, and efficacy of trozamicol in living organisms. This information can be used to improve drug development, optimize treatment strategies, and gain a deeper understanding of the drug's mechanism of action.

(3-iodobenzyl)trozamicol: a high-affinity vesamicol receptor ligand; RN refers to (trans-(-))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3035815
MeSH ID	M0217781

Synonym
meta-iodobenzyltrozamicol
(3s,4s)-1-[(3-iodophenyl)methyl]-3-(4-phenylpiperidin-1-yl)piperidin-4-ol
mibt-3
3-iodobenzyl-4-azavesamicol
4-hydroxy-1-(3-iodobenzyl)-3-(4-phenylpiperidinyl)piperidine
1'-((3-iodophenyl)methyl)-4-phenyl-(1,3'-bipiperidin)-4'-ol trans-(-)-
(m-iodobenzyl)trozamicol
(1,3'-bipiperidin)-4'-ol, 1'-((3-iodophenyl)methyl)-4-phenyl-, trans-(-)-
(3-iodobenzyl)trozamicol
148519-95-3
DTXSID30164003

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (75.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
choline [no description available]	1.98	1	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	1.99	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	1.99	1	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	1.99	1	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
vesamicol vesamicol: RN given refers to parent cpd; structure	2.91	4	piperidines
fluorobenzenes Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.	2.04	1	monofluorobenzenes	NMR chemical shift reference compound
eticlopride eticlopride: blocks dopamine-D2 binding sites; structure given in first source; RN given refers to (S)-isomer	1.99	1	salicylamides
4-fluorobenzyltrozamicol 4-fluorobenzyltrozamicol: a vesamicol receptor ligand; RN refers to (trans-(+))-stereoisomer	2.04	1
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2	1
benzovesamicol benzovesamicol: structure in first source	2.04	1
piperidines Piperidines: A family of hexahydropyridines.	3.5	8

Condition	Relationship Strength	Studies
Brain Disorders [description not available]	1.99	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.99	1
Idiopathic Parkinson Disease [description not available]	1.99	1
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	1.99	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	1.99	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.99	1

(3-iodobenzyl)trozamicol

Description

Cross-References

Synonyms (11)

Research

Studies (8)

Market Indicators

Research Demand Index: 11.97

Study Types